Clinical efficacy of capecitabine and cyclophosphamide (XC) in patients with metastatic breast cancer

Tadahiko Shien, Hiroyoshi Doihara, Keiko Nishiyama, Hiroko Masuda, Tomohiro Nogami, Hirokuni Ikeda, Naruto Taira

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)


Combined low-dose therapy of oral capecitabine (Xeloda) and cyclophosphamide (XC) has been demonstrated to be useful for long-term control of lesions in patients with metastatic breast cancer (MBC) and is aimed at symptomatic alleviation and prolongation of survival. Here, a retrospective review was conducted of MBC patients administered XC at the Okayama University Hospital (OUH), to evaluate responses to XC, adverse events and time to progression (TTP). Twenty patients with MBC received XC between 2006 and 2009. With the exception of 2 elderly patients who were over the age of 70 at the initial examination, all of the patients had received prior treatment with an anthracycline and/or a taxane. No complete response (CR) cases were observed, but partial response (PR) was achieved in 6 patients (30%) and SD in 9 (45%), of whom 5 (20%) sustained SD status for ≥12 months. The median TTP was 6 months (range: 3-27 mo.). Three patients developed Grade 3 adverse events (diarrhea, nausea and stomatitis), but no other patients developed adverse reactions causing interruption of the therapy. XC was safe even in previously treated and elderly MBC patients; moreover, it yielded remarkable clinical responses.

Original languageEnglish
Pages (from-to)231-237
Number of pages7
JournalActa medica Okayama
Issue number4
Publication statusPublished - Aug 2011


  • Chemotherapy
  • Metastatic breast cancer
  • Metronomic

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)


Dive into the research topics of 'Clinical efficacy of capecitabine and cyclophosphamide (XC) in patients with metastatic breast cancer'. Together they form a unique fingerprint.

Cite this